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I. Despite intensive research, the cause of Alzheimer's disease is unknown. 
2. Glutamate is the major excitatory transmitter of the cerebral cortex and hlppo- 
campus and it appears to have an important role in learning and memory. In addition 
to its transmitter function, glutamate is a neurotoxin which has been implicated in 
the pathogenesls of a variety of neurodegeneratlve disorders. 
3. Glutamate toxicity may play a role in the pathogenesis of Alzhelmer's disease. 
4. Disruption of glutamatergic neurotransmission may account, in part, for the 
learning and memory deficits of Alzheimer's disease. 
5. Labeling of the glutamate receptor complex may allow in vivo diagnosis by positron 
emission tomography. 
6. Glutamate receptor ligands may provide a means of therapeutic intervention in 
Alzheimer's disease. 
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i. Introduction 
Dementia of the Alzhelmer type (DAT) is a common and debilitating disease that 
affects about one in six persons over the age of sixty five (Khachaturian, 1985). It is 
characterized by progressive memory and learning deficits and signs of cortical 
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disconnection. The etlology of DAT is unknown and the causes of its clinical manifes- 
tations are Just beginning to be elucidated. Neurochemlcal studies of DAT have revealed 
decreases in cortlcal markers for a variety of neurotransmltters (Wurtman et al., 
1984). In partlcular, the chollnerglc deficit in DAT has received conslderable 
attention (Coyle et al., 1983). However, the relative importance of these neurotrans- 
mltter changes in the pathogenesls and symptomatology of DAT is unknown. 
Glutamate is believed to be the major excitatory transmitter of the cerbral cortex 
and hlppocampus (Fagg and Foster, 1983). Its excitatory actions are mediated by at 
least 3 distinct receptor types named for N-methyl-D-aspartate (NMDA), qulsqualate and 
kalnate, the most specific agonlsts at each of the receptor types (Watk/ns and Evans, 
1981). The distribution and pharmacology of these receptor types have been studied by 
binding techniques, Inclndlag receptor sutoradlography (Foster and Fagg, 1984). There 
is an excellent correspondence between the distribution of receptors and the terminal 
flelds of glutamaterglc pathways (Greenamyre et al., 1984; Greenamyra et sl., 1985a; 
llalpaln et al., 1984; Monaghan and Co,man, 1985). 
The NMDA r e c e p t o r  i s  c o u p l e d  t o  an  i o n  c h a n n e l  t h a t  i s  g a t e d  by  m a g n e s i u m  i n  a 
v o l t a g e - d e p e n d e n t  f a s h i o n  (Nowak e t  a l . ,  1984). D i s s o c i a t i v e  a n e s t h e t i c s ,  l i k e  k e t a m i n e  
and p h e n c y c l i d i n e ,  a r e  n o n c o m p e t i t i v e  a n t a g o n i s t s  of  the  NMDA r e c e p t o r  which a c t  a t  t he  
i o n  c h a n n e l  ( M a r t i n  and Lodge ,  1985) .  The d i s t r i b u t i o n  o f  d i s s o c i a t i v e  a n e s t h e t i c  
b i n d i n g  s i t e s  i s  h i g h l y  c o r r e l a t e d  w i t h  t h a t  of NMDA r e c e p t o r s  (Maragos e t  a l . ,  1986). 
In addition to its role as a neurotransmltter, glutamate is also a neurotoxln 
("excltotoxln'3 which has been implicated in the pathogenesls of neuronal death in a 
variety of neurodegeneratlve diseases (Greenamyre, 1986; Engelsen, 1986). Based on 
experimental evidence, we speculate in this artlcle that (1) glutamate toxicity may 
play a role in the pathogenesls of DAT, (il) disruption of glutamaterglc neurotrans- 
mission accounts for some of the cllnlcal manifestations of DAT, (Ill) labellag of the 
glutamate receptor complex may allow in vlvo diagnosis by means of positron emission 
tomography (PET), and (iv) glutamate receptor llgands may provide a means of 
therapeutic intervention in DAT. 
2. P a t h o ~ e n e s i s  
The n e u r o t o x i c  p r o p e r t i e s  o f  g l u t a m a t e  and  r e l a t e d  compounds  ( " e x c i t o t o x i n s " )  h a v e  
been  r e c o g n i z e d  s i n c e  1957 (Lucas and  Newhouse, 1957). I t  i s  now t h o u g h t  t h a t  g l u t a m a t e  
t o x i c i t y  may p l a y  a r o l e  i n  t h e  c e l l  d e a t h  a s s o c i a t e d  w i t h  H u n t i n g , o u t s  d i s e a s e ,  
o l t v o p o n t o c e r e b e l l a r  a t r o p h y ,  h y p o x t a / i s c h e m i a ,  hypog lycemia  and s t a t u s  e p i l e p t t c u s  
( G r e e n a m y r e ,  1986;  E n g e l s e n ,  1986) .  The NMDA r e c e p t o r ,  i n  p a r t i c u l a r ,  a p p e a r s  t o  
m e d i a t e  e x c i t o t o x i c  e v e n t s  and NMDA a n t a g o n i s t s  a r e  p r o t e c t i v e  i n  h y p o x i a / i s c h e m i a  and 
i n s u l i n - i n d u c e d  hypoglycemia .  N o n c o m p e t i t i v e  a n t a g o n i s t s  a c t i n g  a t  t h e  i on  c h a n n e l  a r e  
s i m i l a r l y  p r o t e c t i v e .  
Al though  t h e r e  have  been  r e c e n t  e x c i t i n g  i n s i g h t s  i n t o  t he  g e n e t i c s  o f  DAT (Se lkoe ,  
1987), t he  b a s i c  p a t h o g e n e t l c  mechan isms  o f  t he  d i s e a s e  r e m a i n  obscure .  S e v e r a l  l i n e s  
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of  ev idence  s u g g e s t  t h a t  g l u t a m a t e  e x c i t o t o x i c i t y  may c o n t r i b u t e  to  t he  p a t h o g e n e s t s  o f  
DAT. I f  s u c h  a m e c h a n i s m  w e r e  a t  work  i n  c o r t e x  and h i p p o c a m p u s  i n  DAT, c e r t a i n  
p r e d i c t i o n s  c o n c e r n i n g  t h e  c o u r s e  o f  t h e  d i s e a s e  would  f o l l o w  l o g i c a l l y  ( T a b l e  1). 
F i r s t ,  because  g l u t a m a t e  r e c e p t o r s  m e d i a t e  t he  t o x i c  e f f e c t s  o f  g l u t a m a t e ,  t h e r e  should  
be s e l e c t i v e  damage to  s t r u c t u r e s  c o n t a i n i n g  t h e s e  r e c e p t o r s .  With p r o g r e s s i o n  of  the  
d i s e a s e ,  and con t inued  damage to  t h e s e  s t r u c t u r e s ,  t h e r e  would u l t i m a t e l y  be a l o s s  o f  
r e c e p t o r s .  A second p r e d i c t i o n  of  t he  e x c i t o t o x i c  h y p o t h e s i s  i s  t h a t  the  d i s t r i b u t i o n  
o f  pa tho logy  in  DAT should  co r r e spond  to  t he  t e r m i n a l  f i e l d s  o f  g l u t a m a t e r g i c  pathways 
in  c o r t e x  and hippocampus.  Thi rd ,  i t  would be expec ted  t h a t  a p p l i c a t i o n  of  e x c i t o t o x i n s  
would r ep roduce  the  neu rochemica l  pa tho logy  of  DAT. Four th ,  i t  m igh t  be expec ted  t h a t  
e x c i t o t o x i n s  would produce p a t h o l o g i c a l  s t i g m a t a  s i m i l a r  to  those  seen  i n  DAT. 
With respect to the first prediction, we have shown a large decrease in glutamate 
receptors in cortex and hlppocampus of DAT brains as compared to age- and post mortem 
delay-matched controls (Greenamyre et al., 1985b; Greenamyre et al., 1987). Glutamate 
binding was normal in the caudate, putamen, claustrum and nucleus basalls of Meynert of 
DAT brains. In the cortex, we have shown that decreased binding was due to a loss of 
receptors and not to a change in their affinity (Greenamyre et al., 1985b). Although 
total glutamate binding was decreased, the most profound losses were found in NMDA- 
dlsplaceable binding. In the initial series of 6 DAT brains studied, NMDA-dlsplaceable 
binding was decreased by about 60Z in temporal cortex and by almost 90Z in the stratum 
pyramldale of the CA1/CA2 region of the hlppocampal formation. In a subsequent series 
of 9 DAT and 9 control brains, in which assays were performed and data were analyzed by 
observers bllnd to the diagnoses, 50-60Z losses of hlppocampal NMDA receptors were 
found (Debowey et al., 1987). Furthermore, as another measure of NMDA receptor 
function, we have shown that dissociative anesthetic binding sites, which presumably 
label the ion channels associated with the NMDA receptor, are also decreased In DAT 
(Maragos et al., 1987). Similar findings in NMDA and dissociative anesthetic binding 
sites have been reported by others (Geddes et al., 1986; Monaghan et al., 1987). 
The s h r u n k e n  d e n d r i t i c  a r b o r  o f  c o r t i c a l  p y r a m i d a l  c e l l s  i n  DAT ( M e h r a e i n  e t  a l . ,  
1975) l i k e l y  r e p r e s e n t s  an a n a t o m i c a l  c o r r e l a t e  of  t h i s  r e c e p t o r  l o s s  and i s  p o s s i b l y  
s econda ry  to  e x c i t o t o x i c i t y .  The e a r l i e s t  n e u r o p a t h o l o g i c a l  ev idence  o f  t o x i c  exposure  
to glutamate is dendritic swelling (Olney et al., 1979), consistent with the known 
dendritic locallzatlon of glutamate receptors (Greenamyre et al., 1984). 
Table 1 
P r e d i c t i o n s  o f  t he  Glutamate ( " E x c i t o t o x t c " )  Hypo thes i s  
1. Damage to  s t r u c t u r e s  c o n t a i n i n g  g l u t a m a t e  r e c e p t o r s  - l e a d i n g  u l t i m a t e l y  t o  a l o s s  
o f  g l u t a m a t e  r e c e p t o r s .  
2. The d i s t r i b u t i o n  o f  pa tho logy  should  co r r e spond  to the  t e r m i n a l  f i e l d s  o f  g l u t a m a t e  
pa thways .  
3. A p p l i c a t i o n s  o f  e x c i t o t o x i n s  should  reproduce  the  neurochemica l  pa tho logy  o f  DAT. 
4. E x c i t o t o x i n s  should  produce n e u r o p a t h o l o g i c a l  s t i g m a t a  s i m i l a r  to  t h o s e  of  DAT. 
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There have been many unsuccessful attempts to correlate the distribution of pathology 
in DAT with specific transmitter systems. Notably, it has been shown that the distri- 
bution of cortical chollnerglc innervatlon does not correlate well with the pathology 
of DAT (Mesulam et al., 1986). In contrast, several laboratories have argued that the 
distribution of senile plaques and neuroflbrillary tangles, the hallmarks of pathology 
in DAT, correlates best with the terminal fields of cortical association pathways 
(Pearson et al., 1985; Rogers and Morrlson, 1985). These pathways are believed to use 
glutamate as their transmitter (Fagg and Poster, 1983), consistent with the second 
prediction of the excltotoxlc hypothesis. In fact, it has been suggested that the 
damage in DAT may propagate along association pathways (Pearson et al., 1985). The 
axons of cortlcocortlcal association pathways terminate primarily in superficial and 
deep layers (V and VI) of other cortical regions (Lorente de No, 1934). Senile plaques 
in DAT are concentrated in these layers and are densest in zones of association fiber 
termination (Pearson et al., 1985; Rogers and Morrlson, 1985). We have noted the 
greatest loss of NMDA receptors in these cortical layers (Greenamyre et al., 1985b). 
Recent evidence suggests that glutamate neurotoxlclty can produce biochemical and 
anatomical changes similar to those seen in DAT. NMDA applied to the cortical surface 
causes retrograde degeneration of chollnerglc neurons in the nucleus basalls of Meynert 
in rats (Sofronlew and Pearson, 1985). This suggests that cortical excltotoxlc events 
might be responsible for the subcortlcal atrophy seen in most DAT brains. Applications 
of excltotoxlns to the hlppocampus have also produced decreases in local levels of 
somatostatln similar to those reported in DAT (McKinney et al., 1982). 
The excltotoxlc hypothesis also suggests that glutamate should be able to produce 
neuropathologlcal changes similar to those of DAT. DeBoni and Crapper-McLachlan (1985) 
demonstrated the induction of paired helical filaments similar to those which make up 
neuroflbrillary tangles, by incubation of cultured human neurons with glutamate. This 
remains to be confirmed using immunohlstochemlstry with antibodies against DAT paired 
helical filaments. Rippocampal NMDA receptor loss, a possible index of excltotoxlc 
damage, correlates with the density of neuroflbrillary tangles (Debowey et al., 1987). 
Together, these data suggest that glutamate toxicity may contribute to the pathogenesls 
of DAT (Table 2). 
Table 2 
The Role of Glutamate in the Pathogenesls of DAT 
- Glutamate is an "excltotoxln" and causes neuronal death. 
- There is a loss of structures containing glutamate receptors in DAT. 
- The pathology of DAT correlates with glutamaterglc association pathways. 
- Excltotoxlns produce retrograde degeneration in the nucleus basalls. 
- Neurochemlcal changes of DAT can be duplicated by excitotoxlns. 
- Glutamate can induce paired hellcal filaments in cultured human neurons. 
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It is important to note that glutamate toxicity need not be the primary event in the 
development of DAT. The primary defect in DAT might be any pathological process leading 
to an impaired ability of neurons to maintain their normal membrane potential. At less 
negative membrane potentials, the voltage-dependent NMDA receptor ion channels would be 
more easily activated. This might lead to more prolonged NMDA receptor-mediated "burst 
firing" and the cell would be even more vulnerable to subsequent excitatory input and 
excltotoxlclty. In this way, even though the primary defect in DAT might be unrelated 
to the glutamatergic system, considerable damage and the pattern of its spread might be 
due to excltotoxiclty. 
3. Clinical Manifestations 
Clinically, DAT is characterized by signs of cortical disconnection, such as the 
agnosias and apraxias, and by progressive learning and memory deficits. Because 
corticocortical and corticohippocampal pathways are believed to use glutamate as their 
transmitter, the decreased number of glutamate receptors we have reported in DAT brains 
would be expected to result in impaired synaptic communication in the cortex and 
hippocampus. 
In addition to this postsynaptlc defect in cortcal and hippocampal communication, 
there is likely to be a presynaptic component to the impaired glutamatergic trans- 
mission. It would be expected that during the progression of the disease, there would 
be a loss of the glutamaterglc neurons which give rise to the association pathways, 
because these neurons themselves receive converging glutamate input. Consistent with 
this, classic morphometrlc studies have shown a marked, selective loss of large 
pyramidal cortical neurons in DAT (Terry et al., 1981; Mann et al., 1986). The degree 
of dementia is correlated with the degree of loss of these cells. These neurons have 
been shown in monkeys to be glutamatergic (Aldo Rustloni, personal communication), but 
confirmatory studies using glutamate immunohistochemistry in human control and DAT 
brains must be performed. 
There is, however, other evidence for loss of glutamate neurons in DAT. Recently, 
Hyman et al (1984) demonstrated a profound loss of cells in the subiculum which project 
to the hlppocampal formation; this effectively isolates the the hippocampus from 
cortical input. Abundant evidence from animal studies suggests that this pathway is 
glutamatergic. More recently, Hyman et al (1986) reported that with loss of these cells 
in DAT, there is an 83% decrease in glutamate levels in the terminal fields of this 
projection. Interestingly, cognitive test scores correlate with CSF glutamate levels in 
DAT patients (Smith et al., 1985). 
In summary, there Is evidence of both pre- and postsynaptic disruption of the 
glutamaterglc association pathways. Such a disturbance might account, in part, for the 
clinical impression of cortical disconnection and its behavioral correlates (Table 3). 
How might be glutamate system be involved in the memory deficits of DAT? Several 
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l a b o r a t o r i e s  h a v e  shown  t h a t  a c t i v a t i o n  o f  t h e  NMDA r e c e p t o r  i s  r e q u i r e d  f o r  t h e  
d e v e l o p m e n t  o f  m o s t  f o r m s  o f  l o n g - t e r m  p o t e n t i a t i o n  (LTP),  a m o d e l  f o r  l e a r n i n g  and  
memory,  and NMDA r e c e p t o r  a n t a g o n i s t s  b l o c k  deve lopmen t  o f  LTP ( C o l l i n g r i d g e ,  1985). 
F u r t h e r m o r e ,  Mor r i s  e t  a l .  (1986) d e m o n s t r a t e d  t h a t  NMDA a n t a g o n i s t s  i m p a i r  s p a t i a l  
d i s c r i m i n a t i o n  l e a r n i n g  and LTP i n  v ivo .  In  humans ,  d i s s o c i a t i v e  a n e s t h e t i c s  suc h  as  
k e t a m i n e ,  which  a r e  n o n c o m p e t i t i v e  NMDA a n t a g o n i s t s ,  c a u s e  a m n e s i a  o f  t he  e v e n t s  i n  t he  
p e r i o p e r a t i v e  p e r i o d .  Thus ,  NMDA r e c e p t o r s  a ppe a r  to  be i n t i m a t e l y  i n v o l v e d  i n  l e a r n i n g  
and memory f u n c t i o n .  The p rofound  l o s s  of  NMDA r e c e p t o r s  i n  c o r t e x  and h ippocampus  o f  
DAT b r a i n s  may p r o v i d e  an e x p l a n a t i o n  f o r  t he  l e a r n i n g  and memory d e f i c i t s  which  a r e  
p r o m i n e n t  i n  DAT. 
Table 3 
The role of glutamate in the symptoms of DAT 
- C o r t i c a l  d i s c o n n e c t i o n :  t h e r e  i s  p r e -  and p o s t s y n a p t l c  e v i d e n c e  f o r  d i s r u p t i o n  o f  
g l u t a m a t e r g i c  a s s o c i a t i o n  pa thways .  
- L e a r n i n g  & memory d e f i c i t s :  NMDA r e c e p t o r s ,  which  a r e  c r u c i a l  to l e a r n i n g  and memory,  
a r e  l o s t  i n  DAT. 
- The degree of dementia correlates with the loss of cortical (? glutamate) pyramldal 
n e u r o n s .  
- C o g n i t i v e  t e s t  s c o r e s  c o r r e l a t e  w i t h  CSF g l u t a m a t e  l e v e l s  i n  DAT p a t i e n t s .  
4. In Vlvo Ima$1n~ 
At p r e s e n t ,  DAT i s  a " d i a g n o s i s  o f  e x c l u s i o n . "  A f t e r  a l l  o t h e r  p o t e n t i a l  c a u s e s  o f  
dementia are ruled out, the tentative diagnosis of DAT can be made; ultimate 
c o n f i r m a t i o n  o f  t h e  d i a g n o s i s  depends  on p a t h o l o g i c a l  s t u d i e s  a t  a u t o p s y .  Even a f t e r  
e x t e n s i v e  work up,  t h e  a n t e m o r t e m  d i a g n o s i s  o f  DAT i s  p roven  i n c o r r e c t  i n  abou t  10 to  
30Z o f  c a s e s  ( K h a c h a t u r i a n ,  1985) .  T h i s  i s  c l e a r l y n o t  a d e q u a t e ,  s i n c e  a n y  p o t e n t i a l  
t h e r a p y  f o r  DAT w i l l  o n l y  be u s e f u l  i f  t h e r e  i s  a means  o f  e a r l y ,  a c c u r a t e  d i a g n o s i s .  
I t  i s  p o s s i b l e  t h a t  t h e  l o s s  o f  g l u t a m a t e  r e c e p t o r s  i n  DAT may be  e x p l o i t e d  f o r  
d i a g n o s t i c  p u r p o s e s .  With  t h e  adven t  o f  PET s c a n n i n g ,  v a r i o u s  r e c e p t o r  complexes  have  
been imaged i n  v tvo  i n  humans (Wagner e t  a l . ,  1983). P e r h a p s ,  the  NMDA r e c e p t o r  complex  
c a n  be l a b e l e d  i n  v t v o  i n  a s i m i l a r  f a s h i o n .  A l t h o u g h  c u r r e n t  NMDA r e c e p t o r  l t g a n d s  
have  l i m i t e d  a c c e s s  t h r o u g h  t he  b l o o d - b r a i n  b a r r i e r ,  d i s s o c i a t i v e  a n e s t h e t i c s  suc h  as  
k e t a m t n e  have  r eady  a c c e s s  to  t he  b r a i n .  S i m i l a r  d r u g s ,  a c t i n g  a t  t h e  NMDA r e c e p t o r  i on  
c h a n n e l ,  may u l t i m a t e l y  prove u s e f u l  f o r  t h e  e a r l y ,  a c c u r a t e  d i a g n o s i s  of  VAT u s i n g  PET 
s c a n n i n g .  
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5. Therapy 
Because e x c i t o t o x i c  mechanisms may p l ay  a r o l e  i n  the  p a t h o g e n e s t s  of  DAT, t r e a t m e n t  
w i t h  r e c e p t o r  a n t a g o n i s t s  m i g h t  seem a t t r a c t i v e  a t  f i r s t  g l a n c e .  H o w ev e r ,  w h e r e a s  
a b e r r a n t l y  e n h a n c e d  g l u t a m a t e r g i c  t r a n s m i s s i o n  may be a c a u s a t i v e  f a c t o r  i n  DAT, a 
r e l a t i v e  " g l u t a m a t e r g i c  d e f i c i t "  may be r e s p o n s i b l e  f o r  t he  c l i n i c a l  m a n i f e s t a t i o n s  o f  
t he  d i s e a s e .  Thus, a l t hough  g l u t a m a t e  r e c e p t o r  b l o c k e r s  migh t  be expec ted  to h a l t  the  
p r o g r e s s i o n  o f  t h e  d i s e a s e ,  t h e y  c o u l d  h a v e  t h e  p a r a d o x i c a l  e f f e c t  o f  e x a c e r b a t i n g  
memory d y s f u n c t i o n  and s i g n s  o f  c o r t i c a l  d i s c o n n e c t i o n .  S i m i l a r l y ,  an a g o n i s t  m i g h t  
h e l p  t he  symptoms but  a c c e l e r a t e  t he  p r o g r e s s i o n  of  t he  d i s e a s e .  Perhaps ,  deve lopment  
of  a p a r t i a l  a g o n i s t  would p rov ide  t he r apy  f o r  bo th  the  symptoms and p a t h o g e n e s i s  o f  
t he  d i s e a s e .  
In this context, it is of interest to examine the apparent success of the 
cholinesterase inhibitor, tetrahydroaminoacridine (THA), in ameliorating the cognitive 
deficits of DAT (Summers et al., 1986). Why should this cholinesterase inhibitor be 
effective when other drugs of this class have been remarkable for their lack of 
efficacy? THA has a complex pharmacology. In addition to its inhibition of chollnester- 
ass, it reduces the duration of anesthesia caused by dissociative anesthetics and 
reverses magnesium chlorlde-induced coma (Shaw and Bentley, 1979; Albin et al., 1974). 
We recently measured the abillty of THA to displace specific binding at dissociative 
anesthetic binding sites (Young et al., 1987).The ICs0 of THAat this site was 30 uM, 
roughly similar to its K m for acetylcholinesterase. Thus, THA is almost as potent at 
dissociative anesthetic binding sites as at the cholinesterase enzyme. Other 
cholinesterase Inhlbitors such as physostlgmlne, edrophonlum and neostlgmlue were much 
weaker displacers, as were a series of potassium channel blockers. These results 
suggest that THA may exert some of its effects at the NMDA receptor complex. The 
beneficial effects of THA in DAT may be attributable to its simultaneous modulation of 
both chollnerglc and glutamaterglc neurotransmlsslon. 
Conc lus ions  
Glutamate is the major excitatory transmitter of the cortex and hippocampus; it is 
also a neurotoxln. Existing data suggests a role for the glutamaterglc system In the 
pathogenesls, clinical manifestations, diagnosis and treatment of DAT. This article is 
intentionally speculative and it will hopefully stimulate more research in this area. 
Perhaps its most important feature is that it provides testable hypotheses. 
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